The Key to Longevity: Scientists Link Calcium Signaling to Slowed Aging
Nature Communications: Disruption of calcium homeostasis leads to accumulation of the S100A6 protein and accelerated aging. Correcting this pathway, particularly through inhibition of serotonin receptors, has shown potential for extending healthy lifespan.
Analytical Review: Calcium, Serotonin, and Aging — How Nature Communications Rewrote the Geroprotection Map
Author: Independent analyst in calcium signaling and drug repositioning in gerontology
Date: June 7, 2026
Event: Publication in Nature Communications on June 5, 2026, of a study by an international team led by Weifang Xiang (Fudan University, Shanghai) showing that disruption of calcium homeostasis leads to accumulation of S100A6, degradation of PARP1, and activation of the cGAS-STING pathway, and that mianserin reverses this process.
For forty years, gerontology has revolved around free radicals, telomeres, and mitochondria. And suddenly it turns out that all along the key "conductor" was right in front of us — the calcium ion. The work by Xiang and colleagues is not just another article showing that "disruption of X leads to aging." It is the first complete description of a signaling cascade from calcium dysregulation to SASP factors, with a clear molecular target for therapy.
As an analyst, I see something more here than a scientific breakthrough. I see a moment when fundamental science and clinical practice converge at a single point: the old antidepressant mianserin, which we have discussed in another context, receives a second (and much more convincing) justification for its geroprotective activity. But there is also a dark side: if calcium homeostasis is so important, then any interventions affecting Ca²⁺ could have unpredictable consequences.
[The Core]: What Is Really Happening
What actually happened is not a "discovery of the calcium aging pathway." What happened is the closing of the loop between three previously disparate observations: (1) that calcium homeostasis is disrupted during aging, (2) that the S100A6 protein accumulates in aging cells, and (3) that cytoplasmic chromatin fragments activate inflammation via cGAS-STING.
Here is the complete scheme constructed by the authors:
- Step 1. Disruption of calcium homeostasis (for any reason — lamin A mutation in progeria or simply age) → increase in intracellular Ca²⁺.
- Step 2. Excess Ca²⁺ binds to the S100A6 protein, which normally should be in the nucleus but accumulates in the cytoplasm under stress.
- Step 3. Cytoplasmic S100A6 recruits the CacyBP protein, which ubiquitinates and sends PARP1 — a key DNA repair enzyme — for degradation.
- Step 4. Without PARP1, damaged DNA is not repaired, and chromatin fragments "leak" into the cytoplasm, forming cytoplasmic chromatin fragments (CCFs).
- Step 5. CCFs activate the cGAS-STING-NF-κB pathway — the central sensor of "foreign" DNA in the cytoplasm.
- Step 6. Activation of NF-κB triggers secretion of SASP factors (IL-6, TNF-α, IL-1β) — the inflammatory phenotype that is "aging" at the tissue level.
The key experiment that proves everything: when the authors treated mice with mianserin (a serotonin receptor antagonist HTR2B/2C), intracellular Ca²⁺ decreased, S100A6 remained in the nucleus, PARP1 was preserved, CCFs did not form, and SASP was reduced. And progeria mice lived 30% longer, while old mice lived longer and healthier.
Insider nuance: the study uses the Lmna^G609G/G609G progeria model — this is not just "mice with a mutation." It is an exact model of Hutchinson-Gilford progeria syndrome, where children age 5-10 times faster. The fact that mianserin worked in this model means the mechanism is sufficient for accelerated aging. And that it worked in naturally aging mice means it is necessary for normal aging. This is a strong claim.
Timeline and Context
The work by Xiang builds on three previous lines of research, and understanding this history is important.
First line: the calcium hypothesis of aging. As early as the 1990s, it was known that calcium channel function declines with age. But this was considered a consequence, not a cause. In 2015-2018, studies emerged showing that correcting calcium homeostasis extends lifespan in worms and flies. However, the mechanism remained unclear.
Second line: S100A6. S100A6 (also known as calcyclin) was discovered as a marker of keratinocyte proliferation in the 1990s. In the 2010s, it was linked to cancer, but not to aging. Xiang shows for the first time that its cytoplasmic accumulation is a driver of aging, not just a correlate.
Third line: cGAS-STING and aging. In 2019-2021, several groups (including Richard Flavell's lab at Yale) showed that CCFs activate cGAS-STING during aging. But what causes CCF formation? Xiang provides the answer: loss of PARP1 due to S100A6.
Key date — June 5, 2026: online publication in Nature Communications. It is not Nature or Cell, but the journal has an impact factor > 15, and importantly, it ensures rapid dissemination (8-10 weeks from acceptance to publication). The submission date was likely in late 2025, with peer review taking about 6 months.
What remains behind the scenes: funding is indicated in the article but not in the abstract. Based on experience, such work is supported by the National Natural Science Foundation of China (NSFC) and possibly the Shanghai Municipal Government. No industrial partners are mentioned — a purely academic project.
Who Wins and Who Loses
Winner #1: Weifang Xiang and his group (Fudan University).
This is their second major work on mianserin in a short time. If the first (which we wrote about earlier) was fragmented, this one creates a complete mechanistic picture. Xiang becomes a world expert on calcium signaling in aging. Expect him to receive invitations to speak at the Gordon Research Conference and Keystone Symposia in 2027, as well as grants from the Hevolution Foundation ($1-3 million) and possibly from the NIH (if collaboration with the US resumes).
Winner #2: Investors in mianserin repositioning (as discussed in previous analyses).
Now they have not one but two independent justifications (first — direct effect on calcium, second — via S100A6-PARP1-cGAS-STING). This doubles the argument for the FDA when filing for a new indication. The risk of rejection decreases, and the startup valuation increases.
Winner #3: Researchers of PARP1 and DNA repair in gerontology.
PARP1 has long been studied only in the context of cancer (PARP inhibitors are already approved for BRCA-mutant tumors, market $3-5 billion). Now it turns out that PARP1 is also a key player in aging, and its preservation (not inhibition) is a geroprotective strategy. This opens a new direction: searching for small molecules that stabilize PARP1 or prevent its ubiquitination.
Loser #1: Manufacturers of PARP inhibitors (AstraZeneca with Lynparza, Merck with Zejula, GSK with Zejula).
If PARP1 is so important for preventing aging, then its chronic inhibition (as in cancer treatment) may accelerate aging in surviving patients. This could lead to lawsuits or, at a minimum, a requirement to add a warning to the label. AstraZeneca sold Lynparza for $3.2 billion in 2025; even a 1% loss due to reputational risks is $32 million.
Loser #2: Those promoting the "antioxidant" paradigm of aging without considering calcium.
Many supplements (vitamin C, E, CoQ10) work by reducing oxidative stress but do not affect calcium homeostasis. If the key driver of aging is Ca²⁺/S100A6/PARP1, then antioxidants may be insufficient. Supplement manufacturers (e.g., Life Extension, NOW Foods) could lose market share if prescription geroprotectors with proven mechanisms emerge.
What the Media Are Not Saying
Non-obvious insight #1 (main): Mianserin affects serotonin receptors HTR2B/2C, but serotonin itself modulates calcium — so this is not a direct effect on calcium, but an indirect one.
The article states: mianserin "antagonizing serotonin receptors HTR2B/2C to lower Ca2+ concentrations." That is, mianserin does not chelate calcium directly — it blocks the signal from serotonin that causes the cell to take up calcium. This means that in patients with impaired serotonin systems (e.g., in Parkinson's disease, where dopamine and serotonin decline), mianserin may work less effectively. Press releases are silent on this.
Non-obvious insight #2: S100A6 is only one of many calcium-binding proteins. Why this one?
The authors did not compare S100A6 with S100B, S100A4, calmodulin, or others. Possibly because in proteomic screening, S100A6 showed the strongest correlation with aging. But this means other calcium-binding proteins may play compensatory roles, and if S100A6 is blocked, they might take over its function. The long-term safety of inhibiting S100A6 is unknown. The article says nothing about this.
Non-obvious insight #3: cGAS-STING is not only about aging but also about immunity. Blocking it could make the body vulnerable to viruses.
Activation of cGAS-STING is a defense mechanism against viral infections (viral DNA in the cytoplasm also activates this pathway). If mianserin reduces cGAS-STING activity by reducing CCFs, it could theoretically impair antiviral immunity. The study did not test mice for viral infections. But if so, mianserin's geroprotection may come at the cost of increased susceptibility to flu or COVID-19.
What is missing about doses and timing: The abstract does not specify the exact doses of mianserin for mice or the duration of treatment. The full article (not yet freely available) contains these data. But based on experience, mouse doses are usually converted to human doses considering metabolism. If the effective dose for mice was 10-20 mg/kg, then for humans it would be 80-160 mg per day — higher than the standard antidepressant dose (30-60 mg). This means that geroprotection may require higher doses, with a risk of sedation (mianserin is sedative).
Forecast: Next 30 Days and 90 Days
Next 30 days (until July 7, 2026):
Expect Xiang's group to release additional data (possibly on Figshare or in the article repository) — proteomic data, raw mouse survival curves, dose dependencies. Also, within 30 days, negotiations will begin with pharmaceutical companies producing mianserin (Shandong Xinhua Pharmaceutical, Teva, Mylan) to sponsor a Phase II study for the new indication.
Additionally, I expect comments from other groups working on cGAS-STING in aging. Richard Flavell (Yale) and Andrea Ablasser (EPFL) will likely issue press releases or editorial articles in Nature Reviews Immunology, confirming or challenging Xiang's conclusions.
Next 90 days (until September 2026):
The most important shift will occur at the clinical trial level. I expect a Phase II study protocol for mianserin in elderly people with aging biomarkers (reduction in IL-6, TNF-α, improvement in physical function) to be submitted. The sponsor could be the Hevolution Foundation (they have a $1.5 billion budget over 5 years) or an academic consortium (e.g., the TAME trial consortium, which is already testing metformin for aging).
Also, within 90 days, the creation of a startup to commercialize mianserin as a geroprotector may be announced — possibly "CalciAge Therapeutics" or "S1006 Therapeutics." Given two publications in Nature Communications, the seed round valuation could reach $15-20 million. Venture capital firms specializing in repositioning (Apple Tree Partners, Sofinnova) will be at the forefront.
Finally, I expect that by September 2026, the first preprint testing a combination of mianserin with existing senolytics (dasatinib + quercetin) will appear. The logic: senolytics kill already senescent cells, while mianserin prevents the emergence of new ones through the calcium mechanism. Synergy could yield +50-70% lifespan extension in mice. If confirmed, this will be the next big news.
Brief summary: Xiang's study is not just "another aging mechanism." It is a complete molecular roadmap from calcium to inflammation, with a clear entry point for therapy — mianserin. Now we have not an empirical observation ("old antidepressant extends lifespan") but a mechanistic justification: it restores calcium homeostasis, preserves PARP1, prevents CCFs, and shuts down cGAS-STING. The next 90 days will show whether the industry is ready to translate this understanding into clinical practice — or whether we will wait another 10 years for someone to conduct a large RCT.
— Editorial Team
